Afp-464 free base
As of the edition of 20 October 2026, Afp-464 free base is a small molecule: stopped in 2013; acts on AHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 4, 3 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Afp-464 free base.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AHR | Aryl hydrocarbon receptor | P35869 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 2 | 0 | 0 | 2 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tigris Pharmaceuticals | Lead sponsor of trials | 2010 to now |